Back to search results

Grid Radiation Therapy for Stage IV Non-Small Cell Lung Cancer

This study is testing a new way to treat stage IV non-small cell lung cancer (NSCLC) that has continued to grow after immunotherapy or chemoimmunotherapy. It combines grid radiation therapy with your ongoing standard immunotherapy. Grid radiation therapy delivers high doses of radiation to small areas of the tumor, which may be more effective at killing cancer cells and relieving symptoms. Researchers want to see how safe this combination is (primary goal) and how well it shrinks tumors in areas not directly treated with radiation. You may be able to join if you are at least 18 years old, have stage IV NSCLC, and have a tumor at least 3 cm that can be treated with grid therapy. This study plans to enroll 20 participants, but its current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 20 participants.
What's involved
You would receive grid radiation therapy, palliative radiation therapy, and standard immunotherapy. You would also have blood samples collected and undergo CT scans. Follow-up appointments will occur for up to 5 years.
Compensation
Not stated in the trial record.
Follow-up
After treatment, you will be followed up at 30 days, then every 8-12 weeks, and every 3 months for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06660407

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer

Recruiting
PHASE2Ages 18+InterventionalTreatment
Mayo Clinic
~20 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:Biospecimen CollectionComputed TomographyImmunotherapyPalliative Radiation TherapySpatially-fractionated Radiation Therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of grade 3+ adverse events
Measured over Up to 3 months post-grid treatment

Conditions

Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Dawn Owen, MD, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2
Stage IV non-small cell lung cancer progressing after immunotherapy or chemoimmunotherapy
Extracranial lesion ≥ 3 cm amenable to grid therapy
Patients with brain metastases are permitted to enroll if all of the following are true:
They are stable (without evidence of progression by imaging ≤ 30 days prior to enrollment and any neurologic symptoms have returned to baseline)
Have no evidence of new or enlarging brain metastases, and
Are not using steroids ≤ 14 days prior to enrollment
Patients may receive conventional palliative radiation or stereotactic body radiotherapy (SBRT) to other metastatic sites (provided there is at least one non-irradiated lesion evaluable for response)
Negative pregnancy test done ≤ 7 days prior to radiation therapy for females of childbearing potential only
Provide written informed consent
Willing to provide mandatory blood specimens for correlative research
Willing to either return to Mayo Clinic for follow-up (during the Active Monitoring Phase of the study) or willing to have virtual visits and blood draws done locally
Estimated by investigator to have a life expectancy \> 3 months

Exclusion

Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Active autoimmune disease requiring systemic treatment, documented history of severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents
NOTE: Exceptions are allowed for:
Vitiligo
Resolved childhood asthma/atopy
Intermittent use of bronchodilators or inhaled steroids
Daily steroids at dose of ≤ 10mg of prednisone (or equivalent)
Local steroid injections
Stable hypothyroidism on replacement therapy
Stable diabetes mellitus on non-insulin therapy
Sjogren's syndrome
Uncontrolled intercurrent illness including, but not limited to:
Ongoing or active infection requiring systemic therapy
Interstitial lung disease
Serious, chronic gastrointestinal conditions associated with diarrhea (e.g., Crohn's disease or others)
Known active hepatitis B (i.e., known positive hepatitis B virus \[HBV\] surface antigen \[HBsAg\] reactive)
Known active tuberculosis (TB)
Symptomatic congestive heart failure
Unstable angina pectoris
Unstable cardiac arrhythmia
Psychiatric illness/social situations that would limit compliance with study requirements (e.g., substance abuse)
History of myocardial infarction ≤ 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
Hypersensitivity to immunotherapy
Previous adverse event attributed to immunotherapy that led to drug discontinuation
History of grade 3+ immune-related adverse event or any grade of immune-related neurologic or ocular adverse event while receiving immunotherapy
Note: Patients who had endocrine adverse events ≤ grade 2 are allowed to enroll if they are stable on appropriate replacement therapy and asymptomatic
Other active malignancy \< 6 months prior to registration
EXCEPTIONS: Non-melanotic skin cancer, papillary thyroid cancer, prostate cancer, or carcinoma-in-situ of the cervix, or others curatively treated and now considered to be at less than 30% risk of relapse
History of allogenic organ transplantation
History of active primary immunodeficiency
Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice)
Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA

What this trial measures

  • Rate of grade 3+ adverse eventsUp to 3 months post-grid treatment

    Will be assessed using any Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Will not utilize a formal statistical design. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be provided. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. Will be considered official if the rate is less than 40% possibly related to study treatment.